PULMOCIDE LIMITED

PULMOCIDE LIMITED

PULMOCIDE LIMITED

Pulmocide is focused on the development of inhaled medicines for the treatmentof viral and fungal infections of the respiratory tract.
Type
B2c
Founded
2013
Raised
$58M
Follow us
Alexa global traffic share
20 Mar 2017
$30,000,000
Venture capital (Series B)

British biotech Pulmocide raises £24m in bid to find treatment for deadly lung diseases

The Telegraph
+1
26 Nov 2013
$27,541,217
Venture capital (Series A)